Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Firms Can't Halt Maryland's 'Price Gouging' Law

Executive Summary

Judge rejects Association for Accessible Medicines' bid for preliminary injunction, but industry can still pursue claims the statute's language is unconstitutionally vague; law goes into effect Oct. 1.

You may also be interested in...



Generic Industry Sues To Halt Maryland's 'Price Gouging' Law

Association for Accessible Medicines says sweeping price restraints on off-patent and generic drugs are vague and will 'unleash a potentially unlimited number of enforcement actions.'

Evolution of Rx Drug Promotion: Researchers Eye Data Brokers, Digital Tools, Global Influencers

US FDA staff acknowledge the challenge of assessing promotions on the internet as experts note trends and topics for future research, including the use of metadata and embedded advertisements, TikTok promotions, and DTC ads extending into countries that prohibit them.

Divided US FDA AdComm Backs Molnupiravir Authorization But Wants More Studies

In 13-10 vote, panel finds reduction in COVID-19 hospitalizations and deaths outweighs risks. Four members say FDA should reconsider authorization if a more effective and safer therapy comes along. They concur molnupiravir should not be recommended for use in pregnancy but available to those who want it.

Topics

Related Companies

UsernamePublicRestriction

Register

GB002232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel